Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of CF 102 in volunteers.

Trial Profile

Phase I trial of CF 102 in volunteers.

Phase of Trial: Phase I

Latest Information Update: 06 May 2008

At a glance

  • Drugs Namodenoson (Primary)
  • Indications Hepatitis B; Hepatitis C; Liver cancer; Liver disorders
  • Focus Adverse reactions
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 06 May 2008 Status changed from recruiting to completed, as reported by Can-Fite.
    • 19 Feb 2008 Can-Fite have reported that the first dose cohort has been completed.
    • 19 Feb 2008 Status changed from initiated to recruiting as reported by Can-Fite Biopharma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top